MiNK Therapeutics (MiNK Therapeutics) EPS (Basic) : $-0.59 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics EPS (Basic)?

MiNK Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2024 was $-0.11. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.59.

MiNK Therapeutics's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.11. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.59.

MiNK Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.11. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was -0.59.

During the past 3 years, the average EPS without NRI Growth Rate was -4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, MiNK Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 3.70% per year. The lowest was -4.40% per year. And the median was -0.35% per year.

MiNK Therapeutics EPS (Basic) Historical Data

The historical data trend for MiNK Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics EPS (Basic) Chart

MiNK Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

-0.93

-0.57

-1.16

-0.83

-0.65

MiNK Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Basic)	Get a 7-Day Free Trial												-0.17	-0.18	-0.15	-0.15	-0.11

MiNK Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

MiNK Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-22.458	-	0)	/	34.360
	=	-0.65

MiNK Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-3.813	-	0)	/	34.643
	=	-0.11

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.59

MiNK Therapeutics (NAS:INKT) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

MiNK Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics (MiNK Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.minktherapeutics.com

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Executives

Agenus Inc	10 percent owner	3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen	director	3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg	director
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin	officer: Treasurer	3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell	director, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan	director	22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum	director	3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni	director	3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner	director	3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius	officer: Chief Technology Officer	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010